NEW YORK, Feb. 17, 2026 — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology enterprise focused on transforming patient outcomes by creating rapid-acting, long-lasting, and accessible mental health treatments, today revealed that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, along with Jason Awe, Ph.D., Vice President of Investor Relations, will engage in fireside chats and conduct one-on-one meetings at the following investor conferences in March.
TD Cowen 46th Annual Health Care Conference
- Format: Fireside chat, taking place on Wednesday, March 4, from 11:50am – 12:20pm EST, and one-on-one meetings
- Location: Boston, Massachusetts
Jefferies 2026 Biotech on the Beach
- Format: One-on-one meetings only, scheduled for Tuesday, March 10
- Location: Miami, Florida
Leerink Global Healthcare Conference
- Format: Fireside chat, occurring on Wednesday, March 11, from 8:00am – 8:30am EST, and one-on-one meetings
- Location: Miami, Florida
Live webcasts of the fireside chats will be available on the investor section of the AtaiBeckley website, under . Archived versions of the webcasts will remain accessible for at least 30 days following the event.
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company committed to transforming patient outcomes through the development of rapid-acting, durable, and convenient mental health treatments. The Company’s pipeline of innovative therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development. Additionally, the Company is advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to drive breakthroughs in mental health via transformative interventional psychiatry therapies that can integrate smoothly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit or follow the Company on and on .
Investor and Media Relations
Investors:
Jason Awe, PhD
VP, Investor Relations
Media:
Charlotte Chorley
Associate Director, Communications
